Factors Influencing Completion of Predictive Testing for Huntington’s Disease (HD)
Objective: To determine if the new simplified testing protocol led to an increase in completion rate of predictive testing for HD, and to study some…A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)
Objective: To determine the efficacy and safety of deutetrabenazine (DTB) as a treatment for tardive dyskinesia (TD). Background: There is no approved treatment for TD,…Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging
Objective: To assess functional connectivity in the premanifest and manifest period of Huntington's disease (HD) by using functional Magnetic Resonance Imaging (fMRI) at high-field (7…Specific in-patient’s rehabilitation improves postural and gait instability in Huntington’s disease
Objective: To evaluate long-term effects of targeted rehabilitation on postural and gait stability in the early and middle stages of Huntington disease (HD). Background: HD…A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome
Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies
Objective: To systematically examine the evidence of striatal molecular alterations in premanifest and manifest Huntington's disease gene expansion carriers (HDGECs) as measured by Positron emission…Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease
Objective: To assess epidemiology and economic burden of falls and fractures among Huntington's disease (HD) patients. Background: The clinical course of HD is characterized by…Evidence of striatal dopaminergic dysfunction Sydenham’s chorea in remission with (99m)Tc-TRODAT-1 SPECT
Objective: To report the findings of reduced striatal dopamine transporter (DAT) density in patients with Sydenham's chorea (SC) in remission assessed by single-photon emission computed…Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report
Objective: To assess feasibility of measuring pathological tau deposition in patients with Huntington's disease (HD) using [18F]-AV-1451 (f.k.a. T807) PET. Background: HD is a progressive…Predictors of quality of life in Huntington’s disease. A longitudinal observational study
Objective: To analyze predictors and progression of quality of life in patients with Huntington's disease (HD), on a longitudinal assessment over two years. Background: HD…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 11
- Next Page »